Xanthine Oxidase Inhibition Attenuates Endothelial Dysfunction Caused by Chronic Intermittent Hypoxia in RatsDopp J.M.a · Philippi N.R.b, d · Marcus N.J.b, d · Olson E.B.c, d · Bird C.E.b, d · Moran J.J.M.a · Mueller S.W.a · Morgan B.J.b, d
aPharmacy Practice Division, School of Pharmacy, bDepartment of Orthopedics and Rehabilitation, and cDepartment of Population Health Sciences and dJohn Rankin Laboratory of Pulmonary Medicine, School of Medicine and Public Health, University of Wisconsin, Madison, Wisc., USA Corresponding Author
Assist. Prof. John M. Dopp, PharmD
School of Pharmacy
University of Wisconsin-Madison
Madison, WI 53705 (USA)
Tel. +1 608 265 9352, E-Mail email@example.com
Background: Xanthine oxidase is a major source of superoxide in the vascular endothelium. Previous work in humans demonstrated improved conduit artery function following xanthine oxidase inhibition in patients with obstructive sleep apnea. Objectives: To determine whether impairments in endothelium-dependent vasodilation produced by exposure to chronic intermittent hypoxia are prevented by in vivo treatment with allopurinol, a xanthine oxidase inhibitor. Methods: Sprague-Dawley rats received allopurinol (65 mg/kg/day) or vehicle via oral gavage. Half of each group was exposed to intermittent hypoxia (FIO2 = 0.10 for 1 min, 15×/h, 12 h/day) and the other half to normoxia. After 14 days, gracilis arteries were isolated, cannulated with micropipettes, and perfused and superfused with physiological salt solution. Diameters were measured before and after exposure to acetylcholine (10–6M) and nitroprusside (10–4M). Results: In vehicle-treated rats, intermittent hypoxia impaired acetylcholine-induced vasodilation compared to normoxia (+4 ± 4 vs. +21 ± 6 µm, p = 0.01). Allopurinol attenuated this impairment (+26 ± 6 vs. +34 ± 9 µm for intermittent hypoxia and normoxia groups treated with allopurinol, p = 0.55). In contrast, nitroprusside-induced vasodilation was similar in all rats (p = 0.43). Neither allopurinol nor intermittent hypoxia affected vessel morphometry or systemic markers of oxidative stress. Urinary uric acid concentrations were reduced in allopurinol- versus vehicle-treated rats (p = 0.02). Conclusions: These data confirm previous findings that exposure to intermittent hypoxia impairs endothelium-dependent vasodilation in skeletal muscle resistance arteries and extend them by demonstrating that this impairment can be prevented with allopurinol. Thus, xanthine oxidase appears to play a key role in mediating intermittent hypoxia-induced vascular dysfunction.
© 2011 S. Karger AG, Basel
Obstructive sleep apnea (OSA) is a medical problem increasingly associated with cardiovascular disease and cardiovascular events such as myocardial infarction and stroke [1,2,3,4,5]. OSA is characterized by intermittent obstruction of the upper airway that results in episodes of hypoxemia, hypercapnia and arousal from sleep. Over time, episodes of OSA increase sympathetic nerve activity , impair function of the vascular endothelium [7,8,9] and alter arterial structure . Even in the absence of clinical cardiovascular disease, patients with OSA exhibit endothelial dysfunction [7,9] and vascular remodeling [10,11,12,13]. Putative mediators of endothelial dysfunction and vascular remodeling are increased concentrations of vasoconstrictor substances (for example, catecholamines, angiotensin II, and endothelin-1) [14,15,16], vascular inflammation [12,17,18] and oxidative stress [18,19,20,21]. One potential source of OSA-induced oxidative stress in vascular endothelium is the cytosolic and membrane-bound enzyme xanthine oxidase. Superoxide anions generated by this enzyme could limit nitric oxide bioavailability, thereby impairing endothelium-dependent vasodilation [22,23], and contribute to vascular remodeling .
During intermittent hypoxia and reoxygenation, xanthine oxidase, NADPH oxidase and ferrylhemoglobin are potent sources of superoxide radicals [25,26,27,28,29]. There are compelling reasons to investigate the role of xanthine oxidase as a source of vascular superoxide in OSA. First, xanthine oxidase activity is increased by hypoxia and by various cytokines such as tumor necrosis factor-α (TNF-α) [30,31,32]. Since patients with OSA experience frequent hypoxic episodes during sleep and TNF-α concentrations are elevated in patients with OSA , xanthine oxidase activity may also be increased in patients with OSA. Second, El Solh et al.  demonstrated that 2 weeks of xanthine oxidase inhibition improved flow-mediated dilation in the brachial arteries of patients with OSA, suggesting that xanthine oxidase plays a role in the vascular impairments caused by OSA.
We previously demonstrated that a 2-week exposure to intermittent hypoxia in rats, an established animal model for OSA, caused impairments in acetylcholine (ACh)- and hypoxia-induced vasodilation in the skeletal muscle and cerebral circulations . In contrast, the exposure had no effect on vasodilator responses to the nitric oxide donor sodium nitroprusside, suggesting that intermittent hypoxia impairs endothelial function by reducing the bioavailability of nitric oxide. In the present study, we investigated the role of xanthine oxidase-derived superoxide anions in causing those impairments. Accordingly, we tested the hypothesis that xanthine oxidase inhibition with allopurinol would prevent intermittent hypoxia-induced endothelial dysfunction.
Adult male Sprague-Dawley rats, in their home cages, were placed into a Plexiglass chamber (1–3 rats per cage) and exposed to intermittent hypoxia for 12 h/day (from 18:00 to 6:00 h) for 14 days. Rats were housed in accordance with space recommendations set forth in the National Institutes of Health Guide for the Care of Laboratory Animals (NIH publication No. 85-23, revised 1985). Oxygen concentrations in the chamber were monitored using a heated zirconium sensor (Fujikura America, Pittsburgh, Pa., USA) connected to solenoid valves that controlled the flow of oxygen and nitrogen. The valves were operated by a microprocessor-controlled timer. The system was set to provide hypoxic exposures at 4-min intervals. During the first minute of each cycle, nitrogen was flushed into the chamber at a rate sufficient to achieve a fraction of inspired oxygen (FIO2) of 0.10 within 60 s. This level of FIO2 was maintained for an additional 60 s. Oxygen was then introduced at a rate sufficient to achieve a FIO2 of 0.21 within 30 s and to maintain this oxygen level for the duration of the 4-min cycle. The oxygen concentrations were checked daily using a TED60T sensor (Teledyne, City of Industry, Calif., USA). Control rats were housed under normoxic conditions adjacent to the hypoxia chamber. In the chamber and the room, temperature was maintained at 24 ± 1°F and relative humidity was maintained between 20 and 70%. Ad libitum access was provided to standard rat chow and water. The protocol was approved by the University of Wisconsin School of Medicine and Public Health Animal Care and Use Committee and conducted in accordance with all institutional rules and regulations for animal research.
Rats were randomized to receive either allopurinol (65 mg/kg/day) or vehicle via oral gavage starting 1 week before and continuing through 2 weeks of experimental hypoxia or normoxia exposure (3 weeks total). There were four experimental groups: (1) rats exposed to intermittent hypoxia that received vehicle; (2) rats exposed to intermittent hypoxia that received allopurinol; (3) rats exposed to normoxia that received vehicle; (4) rats exposed to normoxia that received allopurinol. Allopurinol suspension was prepared by mixing 2,000 mg allopurinol into a 1% (w/v) methylcellulose suspension to achieve a 20-mg/ml concentration. Placebo was a 1% (w/v) methylcellulose vehicle. Klein et al.  demonstrated that an oral dose of 50 mg/kg/day adequately inhibits xanthine oxidase activity in a rat model. However, previous work indicates that hypoxia upregulates xanthine oxidase activity [31,32]; therefore, we used a higher dose (65 mg/kg/day) in order to inhibit the increased xanthine oxidase activity resulting from intermittent hypoxia. Rats receiving vehicle received equivalent daily oral gavage volumes. Daily gavage volumes ranged between 0.5 and 1.1 ml.
The rats were anesthetized (50 mg/kg pentobarbital sodium given intraperitoneally) and the small muscular branch of the femoral artery supplying the gracilis muscle was dissected out. Care was taken to minimize stretching, and the artery was handled only by the surrounding connective tissue. After excision, the arteries were placed in warmed physiological salt solution composed of (in mM): 119.0 NaCl, 4.7 KCl, 1.17 MgSO4, 1.6 CaCl2, 1.18 NaH2PO4, 24.0 NaHCO3, 0.03 EDTA and 5.5 dextrose for transfer to the tissue bath.
The excised gracilis artery was immersed in warmed physiological salt solution bubbled with oxygen (O2), nitrogen (N2) and carbon dioxide (CO2) blended to achieve a gas composition of 19.3 kPa (145 mm Hg) O2, 5.3 kPa (40 mm Hg) CO2 in a superfusion-perfusion chamber (LSI, Burlington, Vt., USA). The proximal and distal ends of the artery were cannulated with glass micropipettes (120 µm, LSI) and secured to the pipettes using 10-0 nylon sutures. The vessel was stretched to the in situ length, and side branches were singly ligated with small strands teased from a 6-0 silk suture (Ethicon, Somerville, N.J., USA) to ensure optimal pressurization. The inflow pipette was connected to a reservoir perfusion system that allows the intraluminal pressure and luminal gas concentration to be controlled. After the artery was mounted on the pipettes, it was allowed to equilibrate for 1 h before baseline measurements were made.
Vessel diameter was measured using television microscopy and a video micrometer (LSI). The level of baseline tone (%) in the vessel was calculated as follows: [(ΔD × Dmax–1) × 100] where Dmax represents the maximum diameter of the vessel at baseline pressure of 10.6 kPa (80 mm Hg) under calcium-free conditions, and ΔD is the increase in diameter from baseline to maximal relaxation. Arteries exhibiting <20% baseline tone were excluded from analysis. In our previous investigations of the effects of chronic intermittent hypoxia on vascular function, the average amount of baseline tone exhibited by gracilis arteries in vitro was approximately 20% . In the present experiments, we required at least 20% baseline tone to ensure that the arteries were healthy and reactive prior to study.
The responses to ACh (10–6M; Sigma, St. Louis, Mo., USA) and sodium nitroprusside (10–4M; Sigma) were assessed in gracilis arteries from each group of rats. In a previous study, we documented a dose-response relationship for ACh and gracilis artery diameter using concentrations of 10–7, 10–6, 10–5 and 10–4M. Based on that analysis, in the present experiment we chose to study responses to 10–6M ACh, a concentration that consistently produced vigorous vasodilations and clear differences in responses of gracilis arteries from rats exposed to intermittent hypoxia versus normoxia. We chose a single high concentration of sodium nitroprusside (10–4) to ensure a brisk vasodilator response to exogenous nitric oxide. When these drugs were administered, the vessel was pressurized to 10.6 kPa (80 mm Hg) by clamping the outflow pipette, and an appropriate amount of drug was added to the superfusate. Vessel diameter was monitored continuously and was measured at the point of its maximum value after the addition of the dilator agent. Vessel responses were measured by an investigator (N.R.P.) blinded to group assignment.
We also assessed vasodilator responses to acute reductions in PO2. Arteries were pressurized to 10.6 kPa (80 mm Hg) by clamping the outflow pipette, and the PO2 of the perfusate and superfusate was lowered to approximately 5.3 kPa (40 mm Hg) by addition of supplemental N2 [35,37]. Vessel diameters were monitored continuously for 20 min, and were measured at the point of maximum value. After acute hypoxic exposures, normoxic conditions were restored in the perfusate and superfusate, and recovery from hypoxia was verified by measuring vessel diameters.
After the response of the arteries to the vasodilator stimuli had been determined, vessel diameter was determined after the vessels were maximally dilated with calcium-free relaxing solution containing the following constituents (in mM): 92.0 NaCl, 4.7 KCl, 1.17 MgSO4·7H2O, 20.0 MgCl·6H2O, 1.18 NaH2PO4, 24.0 NaHCO3, 0.026 EDTA, 2.0 EGTA and 5.5 dextrose.
After the gracilis artery was harvested for vessel reactivity studies, the animal was euthanized and the contralateral gracilis artery was perfused in situ with 4% paraformaldehyde at 10.6 kPa (80 mm Hg) for 45 min and then excised. The vessel was embedded in paraffin, cross-sectioned and stained with hemotoxylin and eosin for vessel morphometry measurements (Histo-Scientific Research Laboratories, Mount Jackson, Va., USA). The sections were visualized on an inverted microscope (TE-2000; Nikon, Melville, N.Y., USA) and were captured using a Spot camera and software for image analysis (MetaVue; Optical Analysis Systems, Nashua, N.H., USA) by a single observer blinded to experimental condition (C.E.B.). In the hematoxylin- and eosin-stained tissue sections, intima-media thickness (IMT) was assessed with line measurement tools (after appropriate calibration) by averaging 12 equally spaced positions around the entire vessel circumference. To calculate the lumen diameter, circumference was determined by averaging the sizes of two circles – one drawn at the ‘peaks’ of the endothelial folds and the other drawn at the ‘valleys’. Wall to lumen ratio was calculated by dividing IMT by lumen diameter.
Blood for hematocrit determination and measurements of plasma lipid peroxidation was withdrawn from the femoral vein in anesthetized rats at the end of the experimental period. Three samples of blood were placed in glass capillary tubes and centrifuged at 11,500 rpm in an IEC MB microhematocrit centrifuge (International Equipment Co., Needham Heights, Mass., USA) for 8 min. All samples were measured using a Spiracrit microhematocrit reading device (Lourdes Instrument Corp., Brooklyn, N.Y., USA) and the results were averaged to yield a single value for each rat. To obtain plasma, blood was anticoagulated with citrate, centrifuged, and plasma was stored at –80°C until analysis. Plasma lipid peroxidation was measured by quantitating 4-hydroxynonenal (4-HNE)-His protein adducts using an enzyme immunoassay kit (Cell Biolabs, San Diego, Calif., USA).
Urine was obtained from the bladder of anesthetized rats with a tuberculin syringe and stored at –80°C until analysis. Urinary uric acid was measured using enzymatic colorimetry (BioVision Inc., Mountain View, Calif., USA). Urinary concentrations of malondialdehyde were measured using a spectrophotometric thiobarbituric acid reactive substances (TBARS) kit to assess lipid peroxidation (a marker of oxidative stress) (Cell Biolabs). Urinary creatinine concentrations were measured using a colorimetric kit (Cayman Chemical, Ann Arbor, Mich., USA). Since urinary creatinine excretion is relatively constant, it can be used as an index to standardize other urinary measurements. Subsequently, malondialdehyde and uric acid concentrations were divided by urinary creatinine concentrations to normalize their rates of excretion. Urinary creatinine was converted from mg/dl to mmol/l by multiplying by 88.4 g/mol so that units were the same as urinary malondialdehyde. Urinary malondialdehyde has been shown to be a marker of lipid peroxidation in animal tissues .
All data are presented as means ± SEM. Vessel reactivity to ACh, sodium nitroprusside and acute hypoxia are expressed as change in diameter (µm). Between-group differences in baseline characteristics, biomarkers of oxidative stress and vascular responses were assessed using an analysis of variance (ANOVA). Post hoc pair-wise comparisons were made using Fisher’s protected least significance difference tests. All data were rank transformed prior to analysis in order to better meet the assumptions of ANOVA. Pooled analysis of intermittent hypoxia versus normoxic control rats (hematocrit) and allopurinol versus vehicle (urinary uric acid) was conducted using a Wilcoxon rank sum test. p values less than 0.05 were considered as significant. The relationship between uric acid excretion and ACh-induced vasodilation was evaluated using Pearson correlation coefficient. All analyses were performed using SAS statistical software version 9.1 (SAS Institute Inc., Cary, N.C., USA).
Rats in the 4 groups were of similar age and weight when studied (table 1). Baseline gracilis artery diameters, maximal diameters and levels of spontaneous baseline tone were similar in the 4 groups, as were hematocrits (table 1). Urinary uric acid divided by urinary creatinine concentrations were lower in allopurinol- versus vehicle-treated rats, providing evidence for xanthine oxidase inhibition (0.18 ± 0.01 vs. 0.23 ± 0.01, p = 0.02).
Gracilis artery responses to ACh differed in the 4 groups (p = 0.001; fig. 1a). Arteries from hypoxia-vehicle rats showed impaired ACh-induced vasodilation compared to those from normoxia-vehicle rats (p = 0.01). ACh-induced vasodilation of arteries from the hypoxia-vehicle rats were also significantly smaller than both the hypoxia-allopurinol (p = 0.001) and normoxia-allopurinol rats (p <0.001). Vessel responses to ACh were not different between the normoxia-vehicle, normoxia-allopurinol and hypoxia-allopurinol groups. Arterial responses to sodium nitroprusside were not significantly different in the four experimental groups (p = 0.43; fig. 1b). A modest negative correlation was found between urinary uric acid and ACh-induced vasodilation (Pearson r = –0.35, p = 0.032; fig. 2).
During acute reductions in perfusate and superfusate PO2, vessels from hypoxia-vehicle rats had somewhat attenuated dilation compared to vessels from rats in the other groups, but the differences were not statistically significant (p = 0.08; fig. 3). Superfusate and perfusate oxygen tensions were similar in the 4 groups during these in vitro tests of hypoxic vasodilation. There were no between-group differences in superfusate O2 tensions for the normoxia (p = 0.13) or acute hypoxia conditions (p = 0.81; table 2).
Neither intermittent hypoxia nor allopurinol influenced gracilis artery morphometry measures. Wall:lumen ratios were 0.40 ± 0.09, 0.49 ± 0.17, 0.46 ± 0.12 and 0.48 ± 0.13 (p = 0.43), while intima-media thickness measurements were 23.9 ± 0.7, 25.7 ± 1.1, 26.1 ± 1 and 24.3 ± 1.1 µm (p = 0.52) in the normoxia-vehicle, normoxia-allopurinol, hypoxia-vehicle and hypoxia-allopurinol groups, respectively.
Urinary concentrations of malondialdehyde corrected for urinary creatinine concentration were similar in all four groups of rats. Urinary malondialdehyde/urinary creatinine concentrations were 1.0 ± 0.1, 1.0 ± 0.1, 0.9 ± 0.1 and 1.0 ± 0.1 in the normoxia-vehicle, normoxia-allopurinol, hypoxia-vehicle and hypoxia-allopurinol groups, respectively (p = 0.95). Plasma HNE-His protein concentrations were also similar in all 4 groups of rats. Mean plasma HNE-adduct concentrations were 9.1 ± 0.5, 9.2 ± 0.3, 9.2 ± 0.4 and 8.4 ± 0.6 µg/ml in the normoxia-vehicle, normoxia-allopurinol, hypoxia-vehicle and hypoxia-allopurinol groups, respectively (p = 0.55).
The major findings of this study are that (1) 2 weeks of intermittent hypoxia exposure impaired ACh-induced vasodilation in skeletal muscle resistance arteries and (2) this impairment was greatly attenuated by in vivo treatment with the xanthine oxidase inhibitor allopurinol. In contrast, neither intermittent hypoxia nor xanthine oxidase inhibition influenced responsiveness to sodium nitroprusside or maximal dilation under calcium-free conditions. Thus, differences in ACh responses between groups cannot be explained by differences in smooth muscle responsiveness to nitric oxide and were not due to structural impairments that limited vessels’ ability to dilate. This study confirms our previous finding that chronic exposure to intermittent hypoxia impairs endothelial function in the skeletal muscle circulation and it extends it by demonstrating that xanthine oxidase plays a role in mediating this vascular dysfunction. The negative correlation we observed between urinary uric acid concentration and ACh-induced vasodilation provides additional support for this notion.
Taken together, our findings of impaired ACh-induced and preserved nitroprusside-induced vasodilation provide indirect evidence that exposure to chronic intermittent hypoxia causes a decrease in the bioavailability of nitric oxide. The precise mechanism by which chronic exposure to intermittent hypoxia reduces nitric oxide is not known; however, previous research from our laboratory indicates that intermittent hypoxia does not diminish endothelial or inducible nitric oxide synthase content in gracilis artery . One often proposed culprit is ‘oxidative stress’ (that is, an upset of the balance between reactive oxygen species and antioxidant capacity) in vascular tissue. Previous investigators have demonstrated that exposure to intermittent hypoxia in rats triggers production of superoxide anion in mesenteric arteries . Because this oxygen radical is known to react quickly with nitric oxide to form peroxynitrite , it may contribute importantly to reduced availability of nitric oxide in the setting of intermittent hypoxia. A potential intracellular source of superoxide during episodes of hypoxia and reoxygenation is NADPH oxidase [25,26,27,28,29,42].
We propose that vascular xanthine oxidase is also an important source of superoxide ion during intermittent hypoxia cycles. During the hypoxia phase, xanthine dehydrogenase is converted to xanthine oxidase and concentrations of xanthine oxidase substrates (that is, hypoxanthine) are increased [32,43]. Once reoxygenation occurs, activated xanthine oxidase uses available oxygen and hypoxanthine to produce superoxide . Inhibition of xanthine oxidase with allopurinol would be expected to reduce vascular superoxide production and hence attenuate the impact of intermittent hypoxia exposure on bioavailability of nitric oxide. In vitro studies indicate that allopurinol in high doses can act as a direct antioxidant, in addition to its effect on xanthine oxidase inhibition [44,45,46]. We consider it unlikely that allopurinol had such an effect in our study, however, because previous investigators determined that direct antioxidant activity is not present in doses up to 100 mg/kg (approximately 1.5 times the dose we used) .
The involvement of xanthine oxidase in mediating impairments in conduit vessel function in patients with clinical OSA has been reported by previous investigators . El Solh et al.  demonstrated that xanthine oxidase inhibition with allopurinol reduced markers of oxidative stress and improved flow-mediated dilation in a conduit artery of the forearm in patients with OSA. Our data expand upon this finding by demonstrating that allopurinol prevents impaired endothelium-dependent vasodilation in skeletal muscle resistance arteries in an experimental model of OSA. We would like to emphasize that these two studies provide complementary, not overlapping, information because concordant responses are not always observed in conduit and resistance arteries [7,47]. The previous and present findings are consistent in that they point to an important role for xanthine oxidase in causing the vascular dysfunction produced by OSA in humans and intermittent hypoxia in rats. We consider it unlikely that xanthine oxidase acts alone in mediating these impairments; nevertheless, nearly full reversal of endothelial dysfunction has been observed after administration of xanthine oxidase inhibitors in smokers and hypertensive subjects [48,49].
In the present study, neither chronic intermittent hypoxia nor xanthine oxidase inhibition influenced measures of arterial thickening in the gracilis artery. In clinical studies, subjects with OSA have increased IMT compared to control subjects [10,11,12]; however, it is likely that these changes develop relatively slowly during years of exposure and, if so, would not be expected to materialize after only 2 weeks of intermittent hypoxia in our animal model. In a separate study from our laboratory that was run concurrently to this one, we found that IMT was unchanged, even after 8 weeks of intermittent hypoxia exposure , although the abundance of both type I and III collagen fibers in gracilis arteries was increased . Our paradigm of chronic exposure to intermittent hypoxia in rats elicits vascular changes consistent with the cardiovascular phenotype of OSA; however, it is possible that characteristics of OSA other than intermittent hypoxia may also play a pathogenetic role. In addition to intermittent hypoxia, patients with OSA experience intermittent hypercapnia and frequent arousals from sleep. Previous evaluations of IMT in patients with OSA have found that high end-tidal CO2, daytime sleepiness and frequency of arousals are all well correlated with increased IMT [50,51]. Our model of chronic intermittent hypoxia produces hypocapnia, rather than hypercapnia, and it does not cause significant sleep disruption. Thus, we suspect that our negative findings regarding vascular structure may be due, at least in part, to the relatively brief exposure period we employed and the failure of our model to mimic all of the insults inherent in clinical OSA, including the presence of comorbid conditions such as increased insulin resistance and obesity.
Although our vascular reactivity data indicate that exposure to intermittent hypoxia limits nitric oxide bioavailability, and previous studies indicate that it causes oxidative stress by stimulating vascular superoxide production [40,52,53,54], we did not detect effects of intermittent hypoxia or xanthine oxidase inhibition on measures of lipid peroxidation and malondialdehyde. One possible explanation is that our stimulus for production of oxidative stress was more subtle than in previous investigations where oxidative stress was documented. We used an oxygen nadir of 10% with a frequency of 15/h for 2 weeks, whereas other studies used oxygen nadirs of 5% [40,52,53,54] and frequencies of 20 or 30/h for as long as 6 weeks [40,52,54,55]. A previous study from our laboratory that employed the present intermittent hypoxia paradigm for durations up to 8 weeks did reveal a significant effect of intermittent hypoxia on urinary excretion of 8-isoprostane PGF2α, another systemic marker of oxidative stress . Many studies that have demonstrated increased oxidative stress in animal models of intermittent hypoxia [40,52,53,54,56] have measured tissue concentrations rather than systemic levels of reactive oxygen species and antioxidant substances. It is possible that our intervention caused oxidative stress in vascular tissue that was not reflected in our systemic measures (that is, urinary malondialdehyde and plasma lipid peroxidation). We would like to emphasize that previous human studies have used systemic markers to demonstrate increased oxidative stress in patients with OSA, diabetes and heart failure, and that these studies report beneficial effects of xanthine oxidase inhibition on systemic markers [34,49,57,58]. It is possible, however, that comorbid conditions such as obesity and increased insulin resistance [59,60] may have contributed to an oxidative stress ‘burden’ in those human subjects that was heightened relative to that experienced by our rats.
Our rat model fails to mimic OSA in humans in a number of important respects. It does not produce upper airway occlusions, negative intrathoracic pressure swings or sleep disruption, and it causes hypocapnia rather than hypercapnia. These features, along with intermittent hypoxia, may be important determinants of OSA-induced vascular dysfunction; nevertheless, our model does recapitulate the OSA phenotype in several ways (that is, endothelial dysfunction , blood pressure elevation [61,62], increased sympathetic nervous system activity  and increased vascular stiffness ). Our model is advantageous in that it allowed us to evaluate the effects of allopurinol on vessel function in the absence of confounding effects of comorbid conditions and other medications. Also, the relatively short (2-week) intermittent hypoxia exposure allowed us to evaluate vascular function in the absence of structural changes that might occur with more prolonged exposure.
We acknowledge that our study has several limitations. First, although our measures of urinary uric acid suggest that xanthine oxidase was inhibited in rats that received allopurinol, we did not make direct measurements of xanthine oxidase activity. We consider it unlikely that decreased urinary uric acid concentrations were due to differences in dietary purine content or decreased renal elimination of uric acid because diet was identical for all animals and excretion of uric acid was accounted for by dividing by urinary creatinine. Therefore, we consider it likely that allopurinol successfully inhibited xanthine oxidase activity. We did not find significantly elevated uric acid levels in intermittent hypoxia-exposed rats treated with vehicle; however, cell culture studies indicate that a much more severe hypoxic stimulus (continuous exposure to 10% oxygen) is required to increase endothelial xanthine oxidase activity . Also, we relied on systemic (plasma and urinary) markers of oxidative stress, not gracilis artery tissue measurements. We did this because we chose to use one gracilis artery for functional studies and the contralateral gracilis artery for analysis of structural changes. Systemic measures of oxidative stress did not differ in the 4 groups of rats. Thus, although our findings indicate xanthine oxidase plays a role in chronic intermittent hypoxia-induced vascular impairments, they do not allow the definitive conclusion that xanthine oxidase inhibition attenuated these impairments via reduction of oxidative stress.
Our study showed that in vivo treatment with allopurinol prevented the development of intermittent hypoxia-induced endothelial dysfunction in skeletal muscle resistance arteries in rats. Our findings are consistent with a previous study that demonstrated improvements in conduit vessel function in patients with established OSA after 2 weeks of allopurinol treatment . Future research is needed to evaluate the potential cardiovascular benefits of long-term xanthine oxidase inhibition as a preventive cardiovascular therapy in patients with OSA.
The authors wish to thank Drs. Glen Leverson and Victoria Rajamanickam in the University of Wisconsin School of Medicine and Public Health Department of Surgery for their statistical assistance. This project was supported by an American College of Clinical Pharmacy Investigator Development Grant (J.M.D.) and by UW Institutional Clinical and Translational Science Award (University of Wisconsin Madison) (KL2) RR025012-01 (J.M.D.) and by NIH grant HL-074072 (B.J.M.).
None to declare.
Assist. Prof. John M. Dopp, PharmD
School of Pharmacy
University of Wisconsin-Madison
Madison, WI 53705 (USA)
Tel. +1 608 265 9352, E-Mail firstname.lastname@example.org
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.